{"nctId":"NCT01680861","briefTitle":"Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium","startDateStruct":{"date":"2012-11"},"conditions":["Transplant; Failure, Kidney"],"count":32,"armGroups":[{"label":"Tacrolimus and Everolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Tacrolimus","Drug: Everolimus","Drug: Corticosteroids"]},{"label":"Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tacrolimus","Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)","Drug: Corticosteroids"]}],"interventions":[{"name":"Tacrolimus","otherNames":["Prograf (brand name)"]},{"name":"Everolimus","otherNames":["Zortress (brand name)"]},{"name":"Enteric Coated Mycophenolate Sodium (EC-MPS)","otherNames":["Myfortic (brand name)"]},{"name":"Corticosteroids","otherNames":["Methylprednisolone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Weight \\> 40 kg.\n* Deceased donor (SCD) or LD.\n* Donor-recipient 1 haplotype matched pairs with a minimum matching of 1 HLA DR antigen.\n* Negative standard cross match for T cells.\n* Pretransplant panel reactive antibodies of \\< 30%.\n* Graft required to be functional, producing at least 100ml of urine within 24hr after transplantation.\n\nExclusion Criteria:\n\n* Previously received or is receiving an organ transplant other than a kidney.\n* Donor organ with a cold ischemic time \\> 48 hours.\n* ABO incompatible donor kidney.\n* Recipients of T cell, or B cell crossmatch positive transplant.\n* Panel reactive antibody (PRA) \\>30%\n* HIV or Hepatitis C virus, or Hepatitis B virus antigenemia.\n* Current malignancy or a history of malignancy\n* Liver disease\n* Uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer\n* Use of warfarin, fluvastatin, or herbal supplements during the study.\n* Use of astemizole, pimozide, cisapride, terfenadine, or ketoconazole.\n* Hypersensitivity to thymoglobulin, IL-2 receptor inhibitor monoclonal antibodies, tacrolimus, everolimus, MPA, or corticosteroids.\n* Pregnant or lactating.\n* Abnormal screening/baseline labs WBC, platelet count, triglycerides, and cholesterol Double kidneys,ECD, pediatric en-block, and donation after cardiac death (DCD)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant","description":"BPAR (biopsy-proven acute rejection) incidence during the first 12 months post-transplant. Grading is determined using standard Banff criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Chronic Allograft Nephropathy (CAI) at 12 Months Post-transplant","description":"Incidence of (biopsy-proven) chronic allograft nephropathy (CAI) \\[interstitial fibrosis and tubular atrophy, using standard Banff criteria\\] at 12 months post-transplant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Loss (Return to Permanent Dialysis or Death)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"eGFR (Calculated Glomerular Filtration Rate), i.e., Renal Function, at 1 Month Post-transplant.","description":"using the abbreviated MDRD formula.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":"8.2"},{"groupId":"OG001","value":"62.1","spread":"6.2"}]}]}]},{"type":"SECONDARY","title":"eGFR (Renal Function) at Month 3 Post-transplant","description":"Renal function as determined by the estimated glomerular filtration rate (eGFR) at 3 months post-transplant, using the abbreviated MDRD formula.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"6.0"},{"groupId":"OG001","value":"65.6","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"eGFR (Renal Function) at 6 Months Post-transplant","description":"using the abbreviated MDRD formula.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":"5.0"},{"groupId":"OG001","value":"63.7","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Discontinuance of Any Study Medication (Tacrolimus, Everolimus, or EC-MPS)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":15},"commonTop":[]}}}